Not All Drugs Approved for Rheumatoid Arthritis Are Equal for Pain Relief

(MedPage Today) — Among rheumatoid arthritis (RA) patients responding to upadacitinib (Rinvoq) or adalimumab, those receiving the former had significantly less residual pain with treatment, according to a post-hoc analysis of data from a phase III trial…